Creating the Thermal Environment for Safely Testing the James Webb Space Telescope at the Johnson Space Center's Chamber A

Chamber A is the largest thermal vacuum chamber at the Johnson Space Center and is one of the largest space environment chambers in the world. The chamber is 19.8 m (65 ft) in diameter and 36.6 m (120 ft) tall and is equipped with cryogenic liquid nitrogen panels (shrouds) and gaseous helium shrouds to create a simulated space environment. The chamber was originally built to support testing of the Apollo Service and Command Module for lunar missions, but underwent major modifications to be able to test the James Webb Space Telescope in a simulated deep space environment. To date seven tests have been performed in preparation of testing the flight optics for the James Webb Space Telescope (JWST). Each test has had a uniquie thermal profile and set of thermal requirements for cooling down and warming up, controlling contamination, and releasing condensed air. These range from temperatures from 335K to 15K, with tight uniformity and controllability for maintining thermal stability and pressure control. One unique requirement for two test was structurally proof loading hardware by creating thermal gradients at specific temperatures. This paper will discuss the thermal requirements and goals of the tests, the original requirements of the chamber thermal systems for planned operation, and how the new requirements were met by the team using the hardware, system flexiblilty, and engineering creativity. It will also discuss the mistakes and successes to meet the unique goals, especially when meeting the thermal proof load

Creating the Deep Space Environment for Testing the James Webb Space Telescope at the Johnson Space Center's Chamber A

Chamber A is the largest thermal vacuum chamber at the Johnson Space Center and is one of the largest space environment chambers in the world. The chamber is 19.8 m (65 ft) in diameter and 36.6 m (120 ft) tall and is equipped with cryogenic liquid nitrogen panels (shrouds) and gaseous helium shrouds to create a simulated space environment. It was originally designed and built in the mid 1960's to test the Apollo Command and Service Module and several manned tests were conducted on that spacecraft, contributing to the success of the program. The chamber has been used since that time to test spacecraft active thermal control systems, Shuttle DTO, DOD, and ESA hardware in simulated Low Earth Orbit (LEO) conditions. NASA is now moving from LEO towards exploration of locations with environments approaching those of deep space. Therefore, Chamber A has undergone major modifications to enable it to simulate these deeper space environments. Environmental requirements were driven, and the modifications were funded, by the James Webb Space Telescope program, and this telescope which will orbit Solar/Earth L2, will be the first test article to benefit from the chamber s new capabilities. To accommodate JWST, the Chamber A high vacuum system has been modernized, additional LN2 shrouds have been installed, the liquid nitrogen system has been modified to remove dependency on electrical power and increase its reliability, a new helium shroud/refrigeration system has been installed to create a colder more stable and uniform heat sink and, the controls have been updated to increase the level of automation and improve operator interfaces. Testing of these major modifications was conducted in August 2012 and this initial test was very successful, with all major systems exceeding their performance requirements. This paper will outline the changes in the overall environmental requirements, discuss the technical design data that was used in the decisions leading to the extensive modifications, and describe the new capabilities of the chamber

Refurbishment of NASA's Johnson Space Center Liquid Nitrogen Bulk Storage Tanks in Preparation for Thermal Vacuum Optical Testing of the James Webb Space Telescope (JWST)

No abstract availabl

Creating the Deep Space Environment for Testing the James Webb Space Telescope (JWST) at NASA Johnson Space Center's Chamber A

Chamber A is the largest thermal vacuum chamber at the Johnson Space Center and is one of the largest space environment chambers in the world. The chamber is 19.8 m (65 ft) in diameter and 36.6 m (120 ft) tall and is equipped with cryogenic liquid nitrogen panels (shrouds) and gaseous helium shrouds to create a simulated space environment. It was originally designed and built in the mid 1960 s to test the Apollo Command and Service Module and several manned tests were conducted on that spacecraft, contributing to the success of the program. The chamber has been used since that time to test spacecraft active thermal control systems, Shuttle DTO, DOD, and ESA hardware in simulated Low Earth Orbit (LEO) conditions. NASA is now moving from LEO towards exploration of locations with environments approaching those of deep space. Therefore, Chamber A has undergone major modifications to enable it to simulate these deeper space environments. Environmental requirements were driven, and modifications were funded by the James Webb Space Telescope program, and this telescope which will orbit Solar/Earth L2, will be the first test article to benefit from the chamber s new capabilities. To accommodate JWST, the Chamber A high vacuum system has been modernized, additional LN2 shrouds have been installed, the liquid nitrogen system has been modified to remove dependency on electrical power and increase its reliability, a new helium shroud/refrigeration system has been installed to create a colder more stable and uniform heat sink, and the controls have been updated to increase the level of automation and improve operator interfaces. Testing of these major modifications was conducted in August of 2012 and this initial test was very successful, with all major systems exceeding their performance requirements. This paper will outline the changes in overall environmental requirements, discuss the technical design data that was used in the decisions leading to the extensive modifications, and describe the new capabilities of the chamber

Applicability of Precision Medicine Approaches to Managing Hypertension in Rural Populations

As part of the Heart Healthy Lenoir Project, we developed a practice level intervention to improve blood pressure control. The goal of this study was: (i) to determine if single nucleotide polymorphisms (SNPs) that associate with blood pressure variation, identified in large studies, are applicable to blood pressure control in subjects from a rural population; (ii) to measure the association of these SNPs with subjects’ responsiveness to the hypertension intervention; and (iii) to identify other SNPs that may help understand patient-specific responses to an intervention. We used a combination of candidate SNPs and genome-wide analyses to test associations with either baseline systolic blood pressure (SBP) or change in systolic blood pressure one year after the intervention in two genetically defined ancestral groups: African Americans (AA) and Caucasian Americans (CAU). Of the 48 candidate SNPs, 13 SNPs associated with baseline SBP in our study; however, one candidate SNP, rs592582, also associated with a change in SBP after one year. Using our study data, we identified 4 and 15 additional loci that associated with a change in SBP in the AA and CAU groups, respectively. Our analysis of gene-age interactions identified genotypes associated with SBP improvement within different age groups of our populations. Moreover, our integrative analysis identified AQP4-AS1 and PADI2 as genes whose expression levels may contribute to the pleiotropy of complex traits involved in cardiovascular health and blood pressure regulation in response to an intervention targeting hypertension. In conclusion, the identification of SNPs associated with the success of a hypertension treatment intervention suggests that genetic factors in combination with age may contribute to an individual’s success in lowering SBP. If these findings prove to be applicable to other populations, the use of this genetic variation in making patient-specific interventions may help providers with making decisions to improve patient outcomes. Further investigation is required to determine the role of this genetic variance with respect to the management of hypertension such that more precise treatment recommendations may be made in the future as part of personalized medicine

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Target 2035-update on the quest for a probe for every protein

Twenty years after the publication of the first draft of the human genome, our knowledge of the human proteome is still fragmented. The challenge of translating the wealth of new knowledge from genomics into new medicines is that proteins, and not genes, are the primary executers of biological function. Therefore, much of how biology works in health and disease must be understood through the lens of protein function. Accordingly, a subset of human proteins has been at the heart of research interests of scientists over the centuries, and we have accumulated varying degrees of knowledge about approximately 65% of the human proteome. Nevertheless, a large proportion of proteins in the human proteome (∼35%) remains uncharacterized, and less than 5% of the human proteome has been successfully targeted for drug discovery. This highlights the profound disconnect between our abilities to obtain genetic information and subsequent development of effective medicines. Target 2035 is an international federation of biomedical scientists from the public and private sectors, which aims to address this gap by developing and applying new technologies to create by year 2035 chemogenomic libraries, chemical probes, and/or biological probes for the entire human proteome

Fine-scale structure of the quasar 3c 279 measured with 1.3 mm very long baseline interferometry

Contains fulltext : 116998.pdf (preprint version ) (Open Access

Applicability of Precision Medicine Approaches to Managing Hypertension in Rural Populations

As part of the Heart Healthy Lenoir Project, we developed a practice level intervention to improve blood pressure control. The goal of this study was: (i) to determine if single nucleotide polymorphisms (SNPs) that associate with blood pressure variation, identified in large studies, are applicable to blood pressure control in subjects from a rural population; (ii) to measure the association of these SNPs with subjects’ responsiveness to the hypertension intervention; and (iii) to identify other SNPs that may help understand patient-specific responses to an intervention. We used a combination of candidate SNPs and genome-wide analyses to test associations with either baseline systolic blood pressure (SBP) or change in systolic blood pressure one year after the intervention in two genetically defined ancestral groups: African Americans (AA) and Caucasian Americans (CAU). Of the 48 candidate SNPs, 13 SNPs associated with baseline SBP in our study; however, one candidate SNP, rs592582, also associated with a change in SBP after one year. Using our study data, we identified 4 and 15 additional loci that associated with a change in SBP in the AA and CAU groups, respectively. Our analysis of gene-age interactions identified genotypes associated with SBP improvement within different age groups of our populations. Moreover, our integrative analysis identified AQP4-AS1 and PADI2 as genes whose expression levels may contribute to the pleiotropy of complex traits involved in cardiovascular health and blood pressure regulation in response to an intervention targeting hypertension. In conclusion, the identification of SNPs associated with the success of a hypertension treatment intervention suggests that genetic factors in combination with age may contribute to an individual’s success in lowering SBP. If these findings prove to be applicable to other populations, the use of this genetic variation in making patient-specific interventions may help providers with making decisions to improve patient outcomes. Further investigation is required to determine the role of this genetic variance with respect to the management of hypertension such that more precise treatment recommendations may be made in the future as part of personalized medicine